However, aberrant β-catenin expression or localization, such as the reduction of β-catenin plasma membrane levels and its aberrant nuclear localization, has been reported and is associated with c-Myc and cyclin D1 overexpression, loss of tumor differentiation, and poor prognosis in human PTC samples (13, 21). The gene discussed is MYC; the disease is neoplasm.